טוען...
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
BACKGROUND: Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-κB ligand, on bone mi...
שמור ב:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3038121/ https://ncbi.nlm.nih.gov/pubmed/19671656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0809003 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|